Crucell N.V. (CRXL) And DSM Biologics Announce PER.C6 Licensing Agreement With Merus For Production Of Monoclonal Antibody Combinations
10/19/2005 5:11:43 PM
Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that Crucell and Merus B.V. have signed a PER.C6(r) research license agreement. This license agreement allows Merus to use the PER.C6(r) cell line for the further development of its Oligoclonics(tm) technology and related products.
comments powered by